Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia
Nucleophosmin 1‐mutated (NPM1mt) acute myeloid leukemia (AML) is associated with a relatively favorable prognosis though long‐term outcomes remain suboptimal without clear predictors identified by therapy.